QIAGEN today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.

Foundation Medicine and Karyopharm Therapeutics said Tuesday they are collaborating on a companion diagnostic for Karyopharm's experimental drug Xpovio (selinexor), which is in development as a maintenance therapy for patients with advanced or recurrent TP53 wild-type endometrial cancer.

Thermo Fisher Scientific said on Tuesday that it has received CE-IVD marking for its Oncomine Dx Express Test, a next-generation sequencing tumor mutation profiling test, and the companion Oncomine Reporter Dx analysis software and has launched them.

Genomenon said Tuesday that it has been named the exclusive gene curation partner for Rady Children's Institute for Genomic Medicine's (RCIGM) recently launched BeginNGS newborn screening panel.

The National Comprehensive Cancer Network on Tuesday published new guidelines for treating children with brain cancer, underscoring the importance of broad molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for patients.

Illumina and Beckman Coulter Life Sciences said on Tuesday that they have partnered on application development for the Biomek NGenius next-generation library preparation system.

Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Integrated DNA Technologies for its forthcoming Biomek NGenius next-generation library preparation system.

Beckman Coulter Life Sciences said on Monday that it has entered into an agreement with Invitae to develop applications for Beckman's new next-generation sequencing library preparation system.

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors

Qiagen and OncXerna Therapeutics said on Monday that they have signed a master agreement to develop a next-generation sequencing companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.